Who IV therapy is not for
Almost everything published about IV therapy is about who it helps. This is the other half: the conditions in which a high-dose infusion can do harm, and why the panel comes before the vein.
A high-dose intravenous infusion is not a supplement in another presentation. It is a clinical procedure, and like every clinical procedure it has a group of people for whom it is contraindicated. That list exists in the literature and almost never appears in the sector's commercial communication.
It goes here, with specific names.
1 · G6PD deficiency
Glucose-6-phosphate dehydrogenase is an enzyme that protects the red blood cell from oxidative stress. When it is missing, high doses of vitamin C can precipitate hemolysis: destruction of red blood cells.
This is not a theoretical risk. In the review of published cases of hemolysis attributed to high-dose vitamin C, around 71% of patients had G6PD deficiency. And in several of those cases the deficiency was not known before the infusion: it was diagnosed after the episode.
The operational consequence is direct: G6PD deficiency should be considered a contraindication for high-dose vitamin C, and therefore it is something to look for beforehand, not discover afterwards.
2 · Compromised kidney function
The oxidative breakdown of vitamin C generates oxalate. At high doses, that oxalate can rise enough to produce oxalate nephropathy, especially in predisposed people.
The literature records cases of kidney failure in that context, and describes the factors that aggravate it: diarrhea, a diet high in oxalate, metabolic acidosis and dehydration. In one published case, a patient developed kidney failure with a creatinine of 8.4 mg/dL against a background of sustained daily vitamin C intake together with chronic diarrhea and a diuretic.
3 · Blood and bone marrow
The review of harm associated with high-dose intravenous vitamin C notes that it is not recommended in the presence of marrow suppression, moderate to severe anemia, hematopoietic disorders, or altered liver and kidney function.
Among the complications described in published cases, besides hemolysis, are acute kidney injury, disseminated intravascular coagulation, oxalosis and methemoglobinemia. And there is a timing figure worth keeping in mind: close to 79% of complications appeared within the first three days.
That is: follow-up does not end when the bag ends.
What all of this means in practice
That the correct order is the reverse of the one usually offered. First the panel, then the indication, and only then the route.
- Blood count and kidney function documented before a high dose, not after.
- G6PD explicitly considered when the protocol involves high doses of vitamin C.
- Hydration status and concomitant medication reviewed, because they are part of the risk.
- Follow-up over the next three days, which is the window where most published complications appeared.
None of this makes IV therapy dangerous. It makes it something that is indicated. A center that puts a line in you without having looked at a panel is not saving you a formality: it is saving itself one.
It is also why at PROFIT7 the Precision Assessment comes before any protocol. It is not a preference about order: it is where exactly the data on this list appears.
Where the evidence stands
What the evidence supports
- That G6PD deficiency should be considered a contraindication for high-dose vitamin C because of the risk of hemolysis.
- That in the review of published cases of hemolysis attributed to high-dose vitamin C, close to 71% of patients had G6PD deficiency, in several cases not previously diagnosed.
- That high-dose vitamin C can induce hyperoxaluria and oxalate nephropathy, aggravated by diarrhea, a diet high in oxalate, metabolic acidosis and dehydration.
- That it is not recommended in marrow suppression, moderate to severe anemia, hematopoietic disorders or altered liver or kidney function, and that close to 79% of the described complications appeared within the first three days.
What it does not yet
- Most of this safety evidence comes from case series and case reports, not from trials designed to measure harm.
- There is no universally established dose threshold below which these risks disappear.
- The real frequency of these complications in the general population receiving wellness IV therapy is not well characterized.
- This list is indicative and does not replace an individual medical assessment: do not use it to rule yourself out, or to clear yourself.
Sources
- Harm of IV High-Dose Vitamin C Therapy in Adult Patients: A Scoping Review Scoping review of harm, complications and the timing window.
- Vitamin C-induced Hemolysis: Meta-summary and Review of Literature Meta-summary of published cases and the proportion with G6PD deficiency.
- Is intravenous vitamin C contraindicated in patients with G6PD deficiency? Clinical discussion of the contraindication in G6PD deficiency.
- Vitamin C-induced hyperoxaluria causing reversible tubulointerstitial nephritis and chronic renal failure Case report of oxalate nephropathy.
This article is general information. It does not replace a medical assessment, and none of its statements should be read as an indication for treatment.
Your data, not an average.
Everything explained here only means something when it is applied to one specific person. That is the starting point.
See the Precision Assessment
